Five out of six were induced by anti-PD1/PDL1 treatment for the treatment of small cell lung cancer (n = 2, one patient treated with atezolizumab and one with nivolumab), lung adenocarcinoma (n = 1, with nivolumab), gastroesophageal junction adenocarcinoma (n = 1, with pembrolizumab) and poorly differentiated neuroendocrine carcinoma (n = 1, with pembrolizumab). This evidence concerns the gene CD274 and neuroendocrine carcinoma.